LT3728254T - Naujieji benzilaminu pakeistieji piridopirimidinonai ir jų dariniai kaip sos1 inhibitoriai - Google Patents

Naujieji benzilaminu pakeistieji piridopirimidinonai ir jų dariniai kaip sos1 inhibitoriai

Info

Publication number
LT3728254T
LT3728254T LTEPPCT/EP2018/086197T LTEP2018086197T LT3728254T LT 3728254 T LT3728254 T LT 3728254T LT EP2018086197 T LTEP2018086197 T LT EP2018086197T LT 3728254 T LT3728254 T LT 3728254T
Authority
LT
Lithuania
Prior art keywords
derivatives
pyridopyrimidinones
benzylamino substituted
sos1 inhibitors
sos1
Prior art date
Application number
LTEPPCT/EP2018/086197T
Other languages
English (en)
Inventor
Juergen Ramharter
Christiane Kofink
Heinz Stadtmueller
Tobias Wunberg
Marco Hans HOFMANN
Anke Baum
Michael Gmachl
Dorothea Ingrid RUDOLPH
Fabio SAVARESE
Markus Ostermeier
Markus Frank
Annika GILLE
Stefan Goepper
Marco Santagostino
Julian WIPPICH
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of LT3728254T publication Critical patent/LT3728254T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
LTEPPCT/EP2018/086197T 2017-12-21 2018-12-20 Naujieji benzilaminu pakeistieji piridopirimidinonai ir jų dariniai kaip sos1 inhibitoriai LT3728254T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17209865 2017-12-21
PCT/EP2018/086197 WO2019122129A1 (en) 2017-12-21 2018-12-20 Novel benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors

Publications (1)

Publication Number Publication Date
LT3728254T true LT3728254T (lt) 2023-05-10

Family

ID=60781991

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/EP2018/086197T LT3728254T (lt) 2017-12-21 2018-12-20 Naujieji benzilaminu pakeistieji piridopirimidinonai ir jų dariniai kaip sos1 inhibitoriai

Country Status (35)

Country Link
US (2) US10829487B2 (lt)
EP (2) EP4219493A1 (lt)
JP (1) JP7189956B2 (lt)
KR (1) KR102746913B1 (lt)
CN (1) CN111372932B (lt)
AR (1) AR114164A1 (lt)
AU (1) AU2018390927B2 (lt)
CA (1) CA3085835A1 (lt)
CL (2) CL2020001501A1 (lt)
CO (1) CO2020007218A2 (lt)
CR (2) CR20210307A (lt)
DK (1) DK3728254T3 (lt)
EA (1) EA202091491A1 (lt)
EC (1) ECSP20040257A (lt)
ES (1) ES2944306T3 (lt)
FI (1) FI3728254T3 (lt)
HR (1) HRP20230400T1 (lt)
HU (1) HUE062076T2 (lt)
IL (1) IL275379B2 (lt)
JO (1) JOP20200154B1 (lt)
LT (1) LT3728254T (lt)
MA (1) MA51290A (lt)
MX (1) MX2020006438A (lt)
MY (1) MY208632A (lt)
PE (1) PE20210163A1 (lt)
PH (1) PH12020550786A1 (lt)
PL (1) PL3728254T3 (lt)
PT (1) PT3728254T (lt)
RS (1) RS64167B1 (lt)
SA (1) SA520412278B1 (lt)
SG (1) SG11202005881YA (lt)
SI (1) SI3728254T1 (lt)
TW (2) TWI810230B (lt)
UA (1) UA126173C2 (lt)
WO (1) WO2019122129A1 (lt)

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018350980C1 (en) 2017-10-18 2024-12-12 Incyte Corporation Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-y gamma inhibitors
ES2944306T3 (es) * 2017-12-21 2023-06-20 Boehringer Ingelheim Int Piridopirimidinonas sustituidas por bencilamino y derivados como inhibidores de SOS1
CR20250050A (es) 2018-09-05 2025-03-19 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
PH12021553105A1 (en) 2019-06-19 2022-07-25 Boehringer Ingelheim Int Anticancer combination therapy
US20230029385A1 (en) * 2019-10-15 2023-01-26 Bayer Aktiengesellschaft 2-methyl-aza-quinazolines
PE20230249A1 (es) 2019-11-08 2023-02-07 Revolution Medicines Inc Compuestos de heteroarilo biciclicos y usos de estos
MX2022006475A (es) 2019-11-29 2022-09-07 Lupin Ltd Compuestos triciclicos sustituidos.
KR20220130126A (ko) * 2019-12-20 2022-09-26 미라티 테라퓨틱스, 인크. Sos1 억제제
MX2022008066A (es) 2019-12-27 2022-08-15 Lupin Ltd Compuestos triciclicos sustituidos.
CN113045565A (zh) * 2019-12-27 2021-06-29 微境生物医药科技(上海)有限公司 新型K-Ras G12C抑制剂
US20230101312A1 (en) * 2020-02-24 2023-03-30 Mirati Therapeutics, Inc. Sos1 inhibitors
CN115244058A (zh) * 2020-04-08 2022-10-25 江苏恒瑞医药股份有限公司 嘧啶并二环类衍生物、其制备方法及其在医药上的应用
AU2021285032A1 (en) 2020-06-02 2022-12-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
CN113801114B (zh) * 2020-06-11 2022-11-18 江苏恒瑞医药股份有限公司 稠合二环杂芳基类衍生物、其制备方法及其在医药上的应用
CN115605479B (zh) * 2020-06-11 2024-05-14 江苏恒瑞医药股份有限公司 吡啶酮并嘧啶类衍生物、其制备方法及其在医药上的应用
EP4171570A1 (en) * 2020-06-24 2023-05-03 Boehringer Ingelheim International GmbH Anticancer combination therapy comprising a sos1 inhibitor and a kras g12c inhibitor
CN113912608B (zh) * 2020-07-10 2023-07-14 江苏恒瑞医药股份有限公司 嘧啶并嘧啶酮类衍生物、其制备方法及其在医药上的应用
EP4186903A4 (en) * 2020-07-24 2024-08-07 Medshine Discovery Inc. Quinazoline compound
WO2022028506A1 (zh) * 2020-08-06 2022-02-10 北京泰德制药股份有限公司 Sos1抑制剂、包含其的药物组合物及其用途
CA3187757A1 (en) 2020-09-03 2022-03-24 Ethan AHLER Use of sos1 inhibitors to treat malignancies with shp2 mutations
AU2021345111B2 (en) 2020-09-15 2025-11-27 Revolution Medicines, Inc. Indole derivatives as Ras inhibitors in the treatment of cancer
WO2022061348A1 (en) 2020-09-16 2022-03-24 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
EP4214204A1 (en) * 2020-09-18 2023-07-26 Bayer Aktiengesellschaft Pyrido[2,3-d]pyrimidin-4-amines as sos1 inhibitors
WO2022083657A1 (zh) 2020-10-20 2022-04-28 苏州泽璟生物制药股份有限公司 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用
WO2022105921A1 (zh) * 2020-11-21 2022-05-27 上海凌达生物医药有限公司 一类嘧啶并杂环类化合物、制备方法和用途
EP4267250A1 (en) * 2020-12-22 2023-11-01 Qilu Regor Therapeutics Inc. Sos1 inhibitors and uses thereof
US20240254117A1 (en) * 2020-12-27 2024-08-01 Shanghai Ringene Biopharma Co., Ltd. Pyrimido-heterocyclic compounds, and preparation method therefor and use thereof
CN114685488A (zh) * 2020-12-31 2022-07-01 南京圣和药业股份有限公司 作为sos1抑制剂的化合物及其应用
CA3203205A1 (en) * 2021-01-19 2022-07-28 Mandar Ramesh Bhonde Pharmaceutical combinations of sos1 inhibitors for treating and/or preventing cancer
WO2022160931A1 (zh) * 2021-01-28 2022-08-04 浙江海正药业股份有限公司 吡啶并嘧啶类衍生物及其制备方法和用途
CN114436976B (zh) * 2021-01-29 2023-07-11 石药集团中奇制药技术（石家庄）有限公司 一种新型喹唑啉类衍生物及其制备和应用
CN117279914A (zh) * 2021-01-29 2023-12-22 南京再明医药有限公司 Sos1抑制剂及其制备方法和应用
CN114835719A (zh) * 2021-02-01 2022-08-02 苏州泽璟生物制药股份有限公司 取代双环并芳杂环胺类抑制剂及其制备方法和应用
CN114835703A (zh) * 2021-02-02 2022-08-02 苏州泽璟生物制药股份有限公司 取代嘧啶并吡啶酮类抑制剂及其制备方法和应用
CN114907341A (zh) * 2021-02-08 2022-08-16 武汉人福创新药物研发中心有限公司 吡啶并嘧啶酮类衍生物及其制备方法和用途
CN116669738B (zh) * 2021-02-09 2026-04-03 苏州阿尔脉生物科技有限公司 一种作为sos1抑制剂的嘧啶并吡啶酮类衍生物、其制备方法及用途
CN114907284B (zh) * 2021-02-10 2023-11-03 石药集团中奇制药技术（石家庄）有限公司 一种具有抗肿瘤活性的化合物及其用途
CN113200981A (zh) * 2021-02-10 2021-08-03 杭州英创医药科技有限公司 作为sos1抑制剂的杂环化合物
WO2022187411A1 (en) 2021-03-02 2022-09-09 Kumquat Biosciences Inc. Heterocycles and uses thereof
CN117062818A (zh) * 2021-03-05 2023-11-14 南京再明医药有限公司 新型sos1抑制剂及其制备方法和应用
CN116917286B (zh) * 2021-03-26 2026-04-28 无锡瓴方生物医药科技有限公司 6-氨基甲酸酯取代的杂芳环衍生物
AU2022250712A1 (en) 2021-03-31 2023-10-05 Sevenless Therapeutics Limited Sos1 inhibitors and ras inhibitors for use in the treatment of pain
GB202104609D0 (en) 2021-03-31 2021-05-12 Sevenless Therapeutics Ltd New Treatments for Pain
WO2022212546A1 (en) * 2021-03-31 2022-10-06 Acerand Therapeutics (Usa) Limited Pyridopyrimidinone compounds
EP4319745A1 (en) * 2021-04-09 2024-02-14 Revolution Medicines, Inc. Use of sos1 inhibitors with ras inhibitors to treat cancers
US20240238294A1 (en) 2021-04-09 2024-07-18 Boehringer Ingelheim International Gmbh Anticancer therapy
CA3213079A1 (en) 2021-04-13 2022-10-20 Kristin Lynne ANDREWS Amino-substituted heterocycles for treating cancers with egfr mutations
EP4074317A1 (en) 2021-04-14 2022-10-19 Bayer AG Phosphorus derivatives as novel sos1 inhibitors
WO2022222875A1 (zh) * 2021-04-19 2022-10-27 昆药集团股份有限公司 一种苯并嘧啶三环衍生物及其制备方法和应用
WO2022223034A1 (zh) 2021-04-23 2022-10-27 上海领泰生物医药科技有限公司 Sos1降解剂及其制备方法和应用
EP4346815A4 (en) * 2021-05-27 2025-04-02 Schrödinger, Inc. HETEROCYCLIC COMPOUNDS AND METHODS OF USE
MX2024000965A (es) 2021-07-27 2024-02-09 Toray Industries Medicamento para el tratamiento y/o prevencion de cancer.
EP4375284A1 (en) * 2021-08-03 2024-05-29 Evopoint Biosciences Co., Ltd. Fused ring compound, pharmaceutical composition, and application thereof
CN116669740A (zh) * 2021-08-16 2023-08-29 华润医药研究院（深圳）有限公司 嘧啶并吡啶类化合物及其制备方法和医药用途
AU2022330732A1 (en) * 2021-08-17 2024-02-15 Cyrus Therapeutics Inc. Sos1 inhibitor and use thereof
WO2023030215A1 (zh) * 2021-08-30 2023-03-09 浙江海正药业股份有限公司 吡啶并嘧啶酮类衍生物及其制备方法和用途
CN117836278A (zh) * 2021-09-02 2024-04-05 上海海和药物研究开发股份有限公司 一种sos1抑制剂、其制备方法及用途
CN117986265A (zh) * 2021-09-14 2024-05-07 北京福元医药股份有限公司 苄氨基取代的嘧啶并吡喃酮衍生物及其组合物、制剂和用途
EP4417607A4 (en) * 2021-09-17 2025-08-06 Nanjing Zaiming Pharmaceutical Co Ltd HETEROCYCLIC COMPOUND USED AS AN SOS1 INHIBITOR AND USES THEREOF
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
CN120923498A (zh) * 2021-11-04 2025-11-11 北京福元医药股份有限公司 苄氨基取代的杂多环化合物及其组合物、制剂和用途
CN115724844B (zh) * 2021-11-22 2024-10-18 石药集团中奇制药技术（石家庄）有限公司 一种具有抗肿瘤活性的杂环化合物及其用途
CN119013272A (zh) 2021-12-01 2024-11-22 勃林格殷格翰国际有限公司 用于治疗癌症的环状2-氨基-3-氰基噻吩及其衍生物
EP4441051A1 (en) 2021-12-01 2024-10-09 Boehringer Ingelheim International GmbH Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes
CR20240233A (es) 2021-12-01 2024-07-17 Univ Vanderbilt Tiofenos 2-amino-3-ciano anulados y derivados para el tratamiento del cáncer
EP4441056A1 (en) 2021-12-01 2024-10-09 Boehringer Ingelheim International GmbH Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2023099623A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
KR20240122545A (ko) * 2021-12-17 2024-08-12 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 항종양 활성을 갖는 헤테로고리 화합물 및 그 용도
WO2023114954A1 (en) 2021-12-17 2023-06-22 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023125737A1 (en) * 2021-12-29 2023-07-06 Silexon Ai Technology Co., Ltd. Heterocyclic compounds and use thereof
US20250154147A1 (en) 2022-01-14 2025-05-15 Jazz Pharmaceuticals Ireland Limited Novel amine-substituted phthalazines and derivatives as sos1 inhibitors
EP4467542A4 (en) * 2022-01-21 2025-07-02 Medshine Discovery Inc CRYSTALLINE FORM OF AN ALLYL METHYLPYRIDOPYRIMIDINE COMPOUND
CN118574830A (zh) * 2022-01-28 2024-08-30 中山优理生物医药有限公司 一种哒嗪并吡啶酮类化合物、其药物组合物及应用
KR20240155872A (ko) * 2022-02-04 2024-10-29 슈뢰딩거, 인크. 헤테로사이클릭 화합물 및 사용 방법
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
CN116768858B (zh) * 2022-03-15 2025-09-12 杭州中美华东制药有限公司 具有kras-sos1抑制或降解活性的嵌合化合物及其用途
US12419962B2 (en) 2022-03-16 2025-09-23 Biotheryx, Inc. Quinazolines, pharmaceutical compositions, and therapeutic applications
GB202203976D0 (en) 2022-03-22 2022-05-04 Jazz Pharmaceuticals Ireland Ltd Tricyclic phthalazines and derivatives as sos1 inhibitors
CA3246750A1 (en) 2022-04-20 2023-10-26 Kumquat Biosciences Inc. MACROCYCLES AND HETEROCYCLES AND THEIR USES
WO2023215256A1 (en) * 2022-05-03 2023-11-09 Revolution Medicines, Inc. Sos1 inhibitors and uses thereof
WO2023215257A2 (en) * 2022-05-03 2023-11-09 Revolution Medicines, Inc. Sos1 inhibitors and uses thereof
KR20250040894A (ko) 2022-05-25 2025-03-25 이케나 온콜로지, 인코포레이티드 Mek 억제제 및 이의 용도
AU2023285116A1 (en) 2022-06-10 2024-12-19 Revolution Medicines, Inc. Macrocyclic ras inhibitors
CN119384422A (zh) * 2022-07-01 2025-01-28 四川汇宇制药股份有限公司 哒嗪并吡啶酮衍生物及其用途
TW202404605A (zh) * 2022-07-07 2024-02-01 大陸商武漢人福創新藥物研發中心有限公司 包含ｓｏｓ１抑制劑的藥物組成物
CN115057847B (zh) * 2022-07-26 2024-01-26 山东百启生物医药有限公司 一种4,6-二氯-5-(1,3-二氧戊环-2-基)-2-甲基嘧啶的制备方法
CN119451960A (zh) * 2022-08-05 2025-02-14 上海艾力斯医药科技股份有限公司 一种稠环化合物、其制备方法及其应用
CN117534667A (zh) * 2022-08-08 2024-02-09 武汉人福创新药物研发中心有限公司 吡啶并嘧啶酮化合物的晶型、其酸式盐、其酸式盐的晶型和用途
JP2025528836A (ja) 2022-08-17 2025-09-02 ツリーライン バイオサイエンシズ インコーポレイテッド ピリドピリミジンＫＲａｓ阻害剤
CN119894893A (zh) 2022-09-16 2025-04-25 拜耳公司 用于治疗癌症的砜取代的吡啶并[3,4-d]嘧啶衍生物
WO2024074827A1 (en) 2022-10-05 2024-04-11 Sevenless Therapeutics Limited New treatments for pain
CN120112538A (zh) 2022-10-13 2025-06-06 拜耳公司 Sos1抑制剂
PE20252677A1 (es) * 2023-02-16 2025-11-24 Cyrus Therapeutics Inc Amidas de azolipiridina piridazinona como inhibidores de sos1
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
EP4688790A1 (en) 2023-04-07 2026-02-11 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024211663A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
AU2024252105A1 (en) 2023-04-14 2025-10-16 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
WO2024216016A1 (en) 2023-04-14 2024-10-17 Revolution Medicines, Inc. Crystalline forms of a ras inhibitor
CN121712509A (zh) 2023-05-04 2026-03-20 锐新医药公司 用于ras相关疾病或病症的组合疗法
EP4720059A1 (en) 2023-05-24 2026-04-08 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
US20250019385A1 (en) 2023-05-30 2025-01-16 Boehringer Ingelheim International Gmbh Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
GB2631397A (en) 2023-06-28 2025-01-08 Sevenless Therapeutics Ltd New treatments for pain
WO2025007000A1 (en) 2023-06-30 2025-01-02 Kumquat Biosciences Inc. Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
TW202515575A (zh) 2023-09-11 2025-04-16 美商金橘生物科技公司 細胞增殖調節劑及其用途
GB2633813A (en) 2023-09-21 2025-03-26 Sevenless Therapeutics Ltd New treatments for pain
AU2024344161A1 (en) 2023-09-21 2026-03-26 Treeline Biosciences, Inc. Spirocyclic dihydropyranopyridine kras inhibitors
IL327306A (en) 2023-10-12 2026-05-01 Revolution Medicines Inc Macrocyclic RAS inhibitors
WO2025083426A1 (en) 2023-10-20 2025-04-24 Sevenless Therapeutics Limited New treatments for pain
WO2025090810A1 (en) 2023-10-25 2025-05-01 Kumquat Biosciences Inc. Use of sos1 inhibitors and amivantamab to treat cancer
AU2024369088A1 (en) 2023-10-25 2026-05-07 Kumquat Biosciences Inc. Combinations of sos-1 inhibitors with osimertinib and/or met inhibitors to treat cancer
WO2025137507A1 (en) * 2023-12-22 2025-06-26 Regor Pharmaceuticals, Inc. Sos1 inhibitors and uses thereof
WO2025146548A1 (en) 2024-01-04 2025-07-10 Sevenless Therapeutics Limited Sos1 inhibitors useful to treat pain and cancer
WO2025171055A1 (en) 2024-02-06 2025-08-14 Kumquat Biosciences Inc. Heterocyclic conjugates and uses thereof
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025202022A1 (en) 2024-03-27 2025-10-02 Bayer Aktiengesellschaft Anticancer macrocyclic quinazoline-based inhibitors of the ineraction between ras and sos1
WO2025210042A1 (en) 2024-04-03 2025-10-09 Boehringer Ingelheim International Gmbh Combination of zongertinib with a sos1 inhibitor for use in the treatment of cancer
WO2025230971A1 (en) 2024-04-30 2025-11-06 Kumquat Biosciences Inc. Macrocyclic heterocycles as anticancer agents
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025245127A1 (en) 2024-05-21 2025-11-27 Treeline Biosciences, Inc. Spirocyclic dihydropyranopyrimidine kras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654307A (en) * 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
US6174899B1 (en) 1998-05-14 2001-01-16 Morton Shulman Orally administered analgesic composition comprising myfadol
JP2010521513A (ja) 2007-03-23 2010-06-24 エフ．ホフマン−ラ ロシュ アーゲー アザ−ピリドピリミジノン誘導体
TWI377944B (en) 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
US8383635B2 (en) * 2008-08-12 2013-02-26 Glaxosmithkline Llc Chemical compounds
MX2011005664A (es) 2008-11-28 2011-06-16 Novartis Ag Inhibidores de hsp90 para tratamiento terapeutico.
EP2376116B1 (en) 2008-12-12 2015-12-09 Boehringer Ingelheim International GmbH Anti-igf antibodies
MX2012004846A (es) 2009-10-29 2012-10-05 Genosco Inhibidores de cinasa.
JP2013544524A (ja) 2010-12-06 2013-12-19 ターポン バイオシステムズ，インコーポレイテッド 生物学的生成物の連続プロセス法
US8846656B2 (en) 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
AR090151A1 (es) 2012-03-07 2014-10-22 Lilly Co Eli Compuestos inhibidores de raf
IN2014MN01754A (lt) 2012-03-14 2015-07-03 Lupin Ltd
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
TW201524952A (zh) 2013-03-15 2015-07-01 Araxes Pharma Llc Ｋｒａｓ ｇ１２ｃ之共價抑制劑
CA2921807C (en) * 2013-08-19 2021-06-29 Council Of Scientific & Industrial Research 3-(4-ethynylphenyl) pyridopyrimidinone compounds and process for preparation thereof useful as potential anticancer agents
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
WO2016077793A1 (en) 2014-11-14 2016-05-19 Children's Hospital Medical Center Sos1 inhibitors for cancer treatment
CN107286180B (zh) * 2016-04-11 2019-07-02 上海勋和医药科技有限公司 杂代吡啶并嘧啶酮衍生物作为cdk抑制剂及其应用
US10898487B2 (en) * 2016-12-22 2021-01-26 Boehringer Ingelheim International Gmbh Benzylamino substituted quinazolines and derivatives as SOS1 inhibitors
US20220235013A1 (en) 2017-03-21 2022-07-28 Bayer Pharma Aktiengesellschaft 2-methyl-quinazolines
ES2944306T3 (es) * 2017-12-21 2023-06-20 Boehringer Ingelheim Int Piridopirimidinonas sustituidas por bencilamino y derivados como inhibidores de SOS1
PH12021553105A1 (en) 2019-06-19 2022-07-25 Boehringer Ingelheim Int Anticancer combination therapy

Also Published As

Publication number Publication date
US10829487B2 (en) 2020-11-10
TW201938557A (zh) 2019-10-01
WO2019122129A1 (en) 2019-06-27
BR112020010123A2 (pt) 2020-11-10
PH12020550786A1 (en) 2021-04-12
ES2944306T3 (es) 2023-06-20
DK3728254T3 (da) 2023-06-06
TW202415656A (zh) 2024-04-16
MX2020006438A (es) 2020-09-17
MA51290A (fr) 2021-03-31
PT3728254T (pt) 2023-05-02
CN111372932B (zh) 2023-11-21
AU2018390927A1 (en) 2020-05-28
MY208632A (en) 2025-05-21
US11814380B2 (en) 2023-11-14
SA520412278B1 (ar) 2022-08-17
EP3728254B1 (en) 2023-02-15
CL2021000907A1 (es) 2021-10-29
CR20200312A (es) 2020-09-11
IL275379B2 (en) 2023-06-01
US20210009588A1 (en) 2021-01-14
JOP20200154A1 (ar) 2020-06-18
CR20210307A (es) 2021-07-27
ECSP20040257A (es) 2020-08-31
TWI870922B (zh) 2025-01-21
EA202091491A1 (ru) 2020-11-13
US20190194192A1 (en) 2019-06-27
PL3728254T3 (pl) 2023-06-12
AR114164A1 (es) 2020-07-29
SI3728254T1 (sl) 2023-06-30
EP3728254A1 (en) 2020-10-28
CO2020007218A2 (es) 2020-06-19
KR102746913B1 (ko) 2024-12-24
CN111372932A (zh) 2020-07-03
CA3085835A1 (en) 2019-06-27
JP2021506864A (ja) 2021-02-22
SG11202005881YA (en) 2020-07-29
HRP20230400T1 (hr) 2023-06-23
IL275379A (en) 2020-07-30
EP4219493A1 (en) 2023-08-02
JP7189956B2 (ja) 2022-12-14
AU2018390927B2 (en) 2023-01-12
RS64167B1 (sr) 2023-05-31
PE20210163A1 (es) 2021-01-26
FI3728254T3 (fi) 2023-05-05
JOP20200154B1 (ar) 2024-04-18
KR20200111163A (ko) 2020-09-28
TWI810230B (zh) 2023-08-01
HUE062076T2 (hu) 2023-09-28
CL2020001501A1 (es) 2020-11-13
UA126173C2 (uk) 2022-08-25

Similar Documents

Publication Publication Date Title
IL275379A (en) Benzylamino-converted pyridopyrimidinones and novel antecedents as SOS1 inhibitors
IL278916A (en) Benzoimidazole derivatives as PAD4 inhibitors
ZA201905811B (en) Novel inhibitors
IL261167A (en) Heteroaryl pad4 inhibitors
IL261170B (en) Carboxamide history used as rsk inhibitors
IL255246A0 (en) Heterocyclic amides as kinase inhibitors
IL259796A (en) Aza-benzimidazole inhibitors of pad4
GB201605126D0 (en) Inhibitors and their uses
IL280641A (en) Converted benzimidazoles as PAD4 inhibitors
ZA201907136B (en) Ip6k inhibitors
IL257283A (en) Chiral phosphoramidates and their history
ZA201703867B (en) Synthesis of copanlisib and its dihydrochloride salt
GB201708457D0 (en) Inhibitors of metallo-beta-lactamases
IL254916A0 (en) Inhibitors and their uses
PT3724196T (pt) Azetidina di-hidrotienopiridinas substituídas e a sua utilização como inibidores de fosfodiesterase
IL274550A (en) Dopamine-B-hydroxylase inhibitors
ZA201705530B (en) 6-morpholinyl-2-pyrazolyl-9h-purine derivatives and their use as pi3k inhibitors
GB201708451D0 (en) Inhibitors of metallo-beta-lactamases
GB201721465D0 (en) Inhibitors
HK40034727A (en) Substituted dihydrothienopyrimidines and their use as phosphodiesterase inhibitors
GB201720189D0 (en) Dopamine-B-hydroxylase inhibitors
GB201705201D0 (en) Novel compounds and their use as kinase inhibitors
GB201505971D0 (en) Inhibitors and their uses
GB201505975D0 (en) Inhibitors and their uses
GB201404332D0 (en) Selective glycosidase inhibitors and uses thereof